The webcast is now available!

An engaging presentation, originally presented at the AMCP Nexus 2016 Meeting

~8,000 rare/orphan diseases have been identified

Tackle the treatment and management of rare/orphan diseases. Review benefit design issues that impact access and the use of treatment of rare/orphan diseases.

  • Analyzing clinical benefit beyond quantifiable metrics
  • Best practices throughout the life cycle of the disease
  • the managed care perspective
  • Decision-making process for managed care pharmacists/medical directors in the treatment of CF
  • How current and emerging therapeutic agents impact cost and HRQoL

Registration




Pre-Test


The following is true about rare/orphan diseases:

For treatment of pulmonary complications of CF, which of the following is TRUE?

The assessment of clinical response to CF therapies includes which of the following?

The Cystic Fibrosis Foundation’s Patient Registry is used to:

How confident are you in your ability to manage formulary decisions and incorporate best practices for the treatment of patients with rare/orphan diseases?

How confident are you in your ability to understand the impact, burden, and pathophysiology of cystic fibrosis?

How confident are you in your ability to understand the treatment landscape of CF and the role of CFTR modulators?

How confident are you in your ability to assess the disease burden of cystic fibrosis beyond lung damage and pulmonary exacerbations?

How confident are you in your ability to understand how formulary decisions may impact patients with CF over their lifetime?